Mechanism of mesenchymal stem cells in treating diabetic kidney disease

Several human studies show positive signals, while research methods and sample sizes continue to develop.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Diabetic kidney disease (DKD) is a serious microvascular complication of diabetes, with symptoms of progressive kidney dysfunction, proteinuria, and fibrosis, ultimately causing end-stage renal disease. Mesenchymal stem cells (MSCs) represent a promising therapeutic approach for DKD, primarily through their paracrine effects. In this review, we concluded the mechanism of MSCs in treating DKD, including the inhibition of inflammation, fibrosis, oxidative stress, and modulate vascular endothelial growth factor (VEGF). Additionally, we discuss strategies to enhance MSC efficacy, such as preconditioning, genetic engineering, and combination therapies with pharmacological agents. Furthermore, we provide an overview of completed clinical trials assessing the effectiveness and safety of MSCs transplantation in DKD patients. The purpose of this review is to highlight the MSCs' potential as an innovative treatment for DKD and to guide future research toward optimizing their therapeutic applications, ultimately improving DKD patients' quality of life.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.